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Background: Standard, 5–7-Fr diameter pacing leads (PLs) can adversely affect atrioventricular
valve (AVV) and venous (superior vena cava [SVC], innominate [INN]) integrities. Although chronic
pacing/sensing performances have been reported on the steroid-eluting, lumenless, 4.1-Fr PL (Model 3830,
Medtronic Inc., Minneapolis, MN, USA), comparative valve and venous effects are largely unknown.
Methods: Patients (n = 134) were divided into two PL groups: Group 1 (n = 65, Model 3830) and Group
2 (n = 69, various 5–7 Fr models) and followed up to 9 years postimplant. Patient demographics, clinical
findings, valve function, and venous dimensions were reviewed. Statistical significance was defined as
P < 0.05.
Results: Patient implant age (mean 16.4 years vs 17.3 years), presence of congenital heart defect (CHD),
and preexisting valve issues were comparable between groups. New or worsening valve insufficiency
occurred in 12% of Group 1 patients (mean follow-up 4.3 ± 2.8 years) and 27% of Group 2 patients (mean
follow-up 6.2 ± 3.5 years; P < 0.05). Significant SVC or INN narrowing was found in 11 % of Group 1 and
24% of Group 2 patients (P = 0.0004). All Group 1 patients <12 years of age showed normal while 50%
of those from Group 2 exhibited stunted SVC or INN growth (P < 0.05).
Conclusion: The lumenless, 4.1-Fr diameter PL offers improved clinical benefits, better AVV integrity,
and venous development compared with larger 5–7-Fr diameter PL and should be considered especially
in younger patients with/without CHD. (PACE 2015; 38:1343–1350)
electrophysiology, clinical, pacing, pediatrics, echocardiography
Introduction
The design of transvenous pacing leads
(PLs) has significantly evolved over the past
decade and has facilitated usage in children and
patients with congenital heart defects (CHDs).
The advanced technology also allows transvenous
pacing in younger patients with smaller body
surface areas. However, to date, there have been
limited data on valvular and vascular effects of
transvenous ventricular PLs in the young. During
transvenous lead implant, as the ventricular PL
is inserted through the atrioventricular valve
(AVV; tricuspid valve in normal hearts and mitral
valve in patients with transposition of the great
arteries), there are potential risks of causing valve
damage resulting in fibrotic reactions leading
to stenosis or insufficiency in the long term.
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Studies among adult patients have shown that
there is an increased prevalence of tricuspid valve
insufficiency (TI) or worsening of any preexisting
TI among patientswho receive transvalvular leads,
ranging between 25% and 29% of older patients
with pacemakers.1–5 Webster et al. reported a 25%
incidence of TI worsening following pacemaker
implant in pediatric and CHD patients.6
Other adverse effects of transvenous PLs in-
clude vascular complications, such as thrombosis
and stenosis, with reported incidences from 35%
to 64%.7,8 Although most venous complications
are subclinical, pacemaker-induced superior vena
cava (SVC) syndrome has also been reported.9–11
The pathophysiology of PL-related venous compli-
cations has been related to mechanical stress from
the pacemaker lead and lead-vascular interactions
which predispose the vessel wall to inflammation,
neointimal proliferation, and progressive fibrotic
reactions.12 These concerns especially apply to
growing children whose venous structure is still
developing.
In 2005, the lumenless 4.1-Fr diameter,
catheter-delivered PL, Model 3830 (Medtronic
Inc., Minneapolis, MN, USA) was approved by
the United States Food and Drug Administration
©2015 Wiley Periodicals, Inc.
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for use in all patients. Compared to conventional
hollow-core, stylet-delivered PLs with diameters
between 5 Fr and 7 Fr, the 4.1-Fr diameter lead
has a solid core. Previous reports have shown
no differences in comparative lead sensing or
pacing performances.13 Several studies have
reported excellent short-term as well as chronic
lead performance (pacing/sensing) outcomes of
the lumenless 4.1-Fr diameter M3830 leads in
pediatric and CHD populations.13–18 Unfortu-
nately, there is limited comparative information
on AVV integrity or vascular (SVC/innominate
[INN]) dimensions between these lead designs
and none in the young or those with CHD.18,19
The aim of our study was twofold: to compare
any AVV effects, either stenosis or insufficiency,
following the implantation of the lumenless 4.1-
Fr diameter leads compared with conventional
5–7-Fr diameter leads among children and young
adults with and without CHD, as well as to
evaluate any chronic adverse vascular effects on
the SVC/INN vein luminal diameters and growth.
Materials
Prior to the introduction of the lumenless
lead in 2005, transvenous PLs implanted in
our institution typically consisted of established
stylet-delivered, hollow-core designs from various
manufacturers, ranging from 5 Fr to 7 Fr diameters.
Since 2002, and for the inclusion of this study,
all of these implanted leads were bipolar, steroid-
eluting, and active-fixation helical designs from
multiple manufacturers (Medtronic Inc.; St. Jude
Medical, St. Paul, MN, USA; Guidant/Boston
Science, St. Paul, MN, USA). The lumenless 4.1-Fr
diameter lead (Medtronic M3830) is also a bipolar,
steroid-eluting helical design with intracardiac
delivery via a steerable peel-away sheath (Select
Secure R© system). The solid core of the M3830
permits the smaller 4.1 Fr diameter. Since August
2005, in most cases, the Medtronic M3830 lead
was implanted at our institution. All leads (4.1
Fr and 5–7 Fr diameters) were 59 cm or 69
cm in length and of a polyurethane/silicone
insulation design. Readily visible differences in
lead diameters are illustrated in Figure 1.
Methods
This is a retrospective chart review of all
patients who received transvenous pacemakers
in our institution during the current era of
steroid-eluting PLs, from 2002 to 2014. The
study was approved by Detroit Medical Center
and Wayne State University School of Medicine
Human Investigation Committee. For the purpose
of determining the lead effects on AVV function,
patients with only transvenous atrial leads were
excluded. To determine any vascular effects on
Figure 1. Exemplary fluoroscopic image in the antero-
posterior projection illustrating diameter differences
between 4.1-Fr and 6-Fr pacing leads. The patient is
post repair of d-TGAwith the intraatrial baffle (Mustard)
surgery. The 4.1-Fr diameter lead (small arrow) is
implanted in the venous (left) atrium while the 6-Fr
diameter lead (large arrow) in the venous (left) ventricle.
Note two previous epicardial leads (one fractured helix)
on right side of the image. d-TGA= dextro transposition
of great arteries.
SVC/INN flow and dimensions, all transvenous
leads (atrial and ventricle) were included. Patients
were divided into two groups: Group 1, all
patients who received the 4.1 Fr (M3830), and
Group 2, patients with standard 5–7-Fr diameter
leads. Further grouping of the 5–7-Fr diameter
leads into subsets was not performed due to
relatively small numbers in each subset as
indicated below. Patient demographic, cardiac
anatomy, indication for pacemaker implantation,
echocardiographic/Doppler findings of preexist-
ing AVV stenosis or insufficiency information
were collected at baseline and compared between
the two groups.
AVV Effects
Data on AVV stenosis or insufficiency
were collected by review of transthoracic
echocardiogram with Doppler studies. A subset of
20% of all studies was independently reviewed by
two pediatric echocardiographers, blinded to PL
design, to ensure intraobserver consistency. AVV
insufficiency (AVVI) was assessed on the basis of
color and spectral Doppler utilizing the standard
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apical four-chamber view, in accordance with
the recommendations of the American Society
of Echocardiography.20 AVVI was classified as
none/trace,mild,moderate, and severe. Post-AVVI
was defined as worsening of AVV competency
postimplant when compared with preimplant
values. The evaluation of AVV stenosis was
performed using transvalvular velocity on the
continuous wave Doppler.21 The degree of valve
stenosis was graded on a scale of none/trivial,
mild, moderate, and severe. The worsening of
AVV function was defined as an increase in the
degree of valve dysfunction severity of at least one
grade. Tricuspid valve function was evaluated
in patients with normal atrioventricular (AV)
concordance andmitral valve function for patients
with AV discordance, for example, patients with
the Mustard intraatrial baffle surgical repair for
dextro (d-) or those with congenital corrected (cc-)
transposition of the great arteries [TGA]). Echocar-
diogram/Doppler studies performed within
1 month prior to pacemaker implantation
were reviewed and analyzed in all patients as a
baseline. Postimplant echocardiograms performed
at 1 month and at least annually thereafter were
reviewed and analyzed for up to 9 years.
Systemic Venous Effects and Dimensions
The luminal diameters of the INN vein and
SVC were measured online from venograms per-
formed during cardiac catheterization studies at
implant (Syngo Dynamics—Siemens Healthcare,
Forchheim, Germany). Since a previously pub-
lished study has shown that vascular diameters
in growing children are more closely correlated
with height rather than weight or body surface
area, the venous diameters were measured in four
regions, distal INN, mid-INN, INN-SVC junction,
andmid-SVC, and compared to the expected value
in relation to height according to the published
formula: distal INN (2.07 + 0.081 height), mid-
INN (1.73 + 0.086 height), INN-SVC (2.4 + 0.072
height), and mid SVC (3.2 + 0.093 height).22
For patients over the age of 12 years, age-related
changes in venous diameters were not observed
and assumed to approximate adult values.22
Conventionally, significant narrowing of the SVC
or INN was defined as the postimplant vessel
luminal diameter at the site of obstruction more
than 60% of the more distal vessels.23 Additional
assessment of the SVC/INN flow patterns were
obtained during pre- and all postlead implant
echocardiogram/Doppler studies.
In evaluation of lead-related systemic venous
effects, patients who received any transvenous
lead (atrial, ventricular, or both) were subdivided
depending on lead number and type. In this
manner, vascular effects among patients with
either one or two transvenous 4.1-Fr PLs were
compared with effects from patients with either
one or two standard 5–7-Fr leads as well as from
patients with both the lumenless and standard
leads.
Ventricular Lead Implantation
Indications for pacemaker implant followed
standard guidelines for pediatric and congenital
heart patients. Prior to the pacemaker implan-
tation, all patients underwent a standard left
and right heart catheterization study to evaluate
hemodynamic status and venograms for vascular
patency, especially among those with repaired
CHD. Subclavian veins or axillary veins were
entered percutaneously. PLs were positioned to
obtain optimal pacing threshold, sensing, and
contractility.24 Specific attempts at “His/para-His”
pacing were not performed due to concerns for
elevated pacing thresholds.25,26 Follow-up data
up to 9 years after implant included information
on AVV function during follow-up echocardio-
gram/Doppler studies and SVC venogram during
any subsequent cardiac catheterizations.
Statistical Analysis
Statistical analysis was performed using
SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA). Since AVV stenosis or insufficiency is a
categorical variable, changes in the degree of valve
stenosis or insufficiency were evaluated over time
using the nonparametric Wilcoxon signed-rank
test. A paired t-test was used to compare the
demographic data. Agreement between the two
echocardiographers’ reading was calculated using
the kappa (κ) statistic for categorical variables.
Variables with a lower 95% confidence limit of κ >
0.4 were considered to have acceptable agreement.
Finally, paired and nonpaired t-test was used to
compare significance narrowing of systemic veins.
Statistical significance was defined as P < 0.05.
Results
During the time frame of this study, 255 PLs
were implanted in 182 patients, of whom 134
patients received ventricular leads. Patient ages
ranged between 5 years and 45 years (mean 16.8
± 8.3 years), with 75 (56%) males. There were
65 patients who received the 4.1-Fr M3830 lead
(Group 1) and 69 patients with standard 5–7-Fr
diameter leads (Group 2). Of these 69 patients
with leads from Group 2, a breakdown of specific
lead diameters showed that diameters ranged from
5 Fr to 5.9 Fr (n = 22), 6 Fr to 6.9 Fr (n =
30), and 7 Fr to 7.4 Fr (n = 17). Relatively small
numbers per subset of Group 2 precluded separate
comparisons with the 4.1-Fr diameter lead group.
Patient demographic data in both groups were
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Table I.
Transvenous Ventricular Leads Demographics
Group 1 Group 2 P Value
n = 134 65 69 NS
Age at implant
(years) †
16.4 ± 7.8 17.3 ± 8.7 NS
Weight at implant
(kg) †
59.6 ± 25.7 57.2 ± 22.5 NS







Septal defects 8 7 NS







cc-TGA 6 5 NS
Others‡ 7 4 NS
†Mean ± standard deviation.
‡Other forms of CHD include congenital aortic stenosis, subaortic
stenosis, truncus arteriosus, Ebstein’s anomaly of tricuspid valve.
cc = congenitally corrected; cc-TGA = congenitally corrected
transposition of great arteries; CHD = congenital heart defects;
d-TGA = dextro transposition of great arteries; PA-VSD =
pulmonary atresia, ventricular septal defect; TGA = transposition
of great arteries; TOF = tetralogy of Fallot.
comparable and are shown inTable I. For review of
vascular dimensions, all patients (those with atrial
plus ventricular leads) were studied. However,
only those patients who received ventricular leads
were included for valvular issues. Among the 134
patients, 90 (67%) had undergone repair of various
anatomical CHD such as d-TGA with an atrial
baffle (Mustard procedure) AV or V septal defects,
tetralogy of Fallot with or without pulmonary
valve replacement, and hypertrophic cardiomy-
opathy with myomectomy. Patients without surgi-
cally repaired CHD included thosewith congenital
complete AV block, congenital long QT syndrome,
and hypertrophic cardiomyopathy. Presence of
congenital heart conditions and AVV morpholo-
gies were comparable between groups. There
were no acute complications observed during lead
implantation in either group. One lead in Group
1 (4.1 Fr) and four leads in Group 2 (Standard
5–7 Fr) required replacement secondary to lead
fracture or displacement. These incidents were
detected upon follow-up and occurred beyond
6 months and within 2–3 years postimplant.
There were no other complications noted. Since
the larger diameter leads were utilized prior to
2005 in our institution, longer follow-up data,
as expected, were available compared to the
lumenless 4.1-Fr lead that was utilized only
after August 2005. Therefore, comparative 9-year
(August 2005–2014) follow-up was available in all
69 patients from Group 2 but only 15 patients from
Group 1. At least 3-year follow-up postimplant
data were available on all patients.
AVV Effects
To diminish observer variability, a subset
of echocardiographic images (20%) were blindly
and independently reviewed by two echocardio-
graphers demonstrating nearly perfect agreement
(κ = 0.85 and 0.89) with the initial echocardio-
graphic/Doppler interpretation of AVV effects. In
comparison between groups, nine (14%) of pa-
tients in Group 1 and 11 (16%) of Group 2 patients
exhibited some preexisting AVVI (P = NS). During
the comparative 9-year postlead implant follow-
up interval, review of valve integrities showed
that eight (12%) patients in Group 1 exhibited
worsening of AVVI but without symptoms while
19 (27%) patients in Group 2 (P < 0.05) had
clinically symptomaticworsening ofAVVI (Fig. 2).
Of these latter patients, three underwent surgical
tricuspid valvuloplasty due to hemodynamically
significant right atrial dilatation and refractory
atrial arrhythmia. There were no differences in
AVV assessment between the preprocedure and
first follow-up echocardiogram/Doppler study at
the 1-month interval (P = NS). Onset of AVVI
was noted within 27.4 ± 15.8 months at follow-
up: five patients with preexisting AVVI from
Group 1 developed worsening of AVVI on one
ordinal scale (mild to moderate or moderate to
severe), compared to all patients from Group 2
(P < 0.05). While there were no patients from
Group 1, three patients from Group 2 exhibited
extreme AVVI more than one ordinal scale. New
onset AVVI, all detected within the first 3 years
postimplant, occurred in four patients from Group
1 and eight patients from Group 2. The change in
AVVI between two groups is shown in Table II.
There were no significant changes in ventricular
function at times of valve insufficiency detection.
AVV stenosis was not detected in any patient at
pre- or postimplantation evaluations.
Systemic Venous Effects and Lead Number
Since many patients with ventricular also
had atrial leads, venous effects were evaluated
based on lead number and type. SVC or INN
luminal diameters more than 60% narrowing were
defined as having obstruction.23 All patients had
baseline venograms performed at the time of
lead placement. Postlead implant venograms to
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Figure 2. Right: Transthoracic echocardiogram/Doppler study in the four-chamber view,
demonstrating amoderate-severe degree of tricuspid valve insufficiency (arrow) associated with a
6-Fr diameter lead. Left: With the Doppler signal off, the 6-Fr diameter pacemaker lead is readily
visible traversing through the tricuspid valve.
evaluate vascular patency were obtained at the
time of any required generator change or other
catheterization studies performed for clinical
reasons. Due to the time frame of this review, all
69 patients (100%) who had received standard 5–
7-Fr PLs (Group 2) underwent postlead implant
venograms at mean follow-up interval of 6.8 ± 2.6
years. There were 61 patients with either one or
two transvenous 4.1-Fr PLs (Group 1). However,
due to the shorter postimplant time intervals,
and limited availability of repeat catheterization
studies, venograms were available in only 35
(57%) patients from this group at mean follow-up
interval of 4.2 ± 1.8 years.
The overall incidence of angiographically
significant venous obstruction was 21% among
all patients. As a comparison between lumenless
versus standard leads, there was significantly less
venous obstruction associated with the 4.1-Fr
diameter lead (P = 0.0004). Of those 35 patients
from Group 1 with follow-up venograms, there
were 10 patients with only one 4.1-Fr diameter
lead and none of these patients showed any
evidence of venous obstruction. On the other
hand, among patients with two 4.1-Fr diameter
leads (N = 25), four (16%) met criteria for
obstruction. Among the 69 patients with the larger
diameter (5-6-7 Fr) leads, 33 had received one and
63 patients had two leads. Of these, eight of 33
(24%) and 15 of 63 (23%) showed obstruction
(Fig. 3). Finally there were 18 patients with both
the lumenless as well as standard leads. Of these,
a postimplant venogram was performed in all
patients at a mean follow-up interval of 5.4 ± 2.3
years. This demonstrated obstruction in four of 18
(22%) patients.
In comparison among lead type and number,
there was significantly less obstruction associated
with a single 4.1 Fr versus single 5–7-Fr leads
(P = 0.0002) as well as between two 4.1 Fr
versus two 5–7-Fr diameter leads (P = 0.0002).
All 10 patients with 4.1-Fr leads implanted when
they were less than 12 years of age showed
no difference in luminal venous diameters on
follow-up, adjusted for height, between pre- and
postimplant, while six of 12 patients (50 %)
younger than 12 years with 5–7-Fr diameter leads
showed stunted growth of the SVC and INN veins,
as evident by less than a 60% diameter increase
upon follow-up venograms (P < 0.05).
Discussion
Compared with pacemaker implantation
among older patients with normal cardiac
anatomy, PLs in children and patients with CHDs
PACE,Vol. 38 November 2015 1347
BHARMANEE, ET AL.
Table II.
Atrioventricular Valve Insufficiency Data
Group 1 Group 2 P Value
n = 134 65 69
Preexisting AVVI 9 (14%) 11 (16%) NS
AVVI worsening
postimplant






















AVVI = atrioventricular valve insufficiency.
often pose a challenge to implanting physicians,
due to relatively smaller patient size, venous
dimensions, wide anatomic cardiac diversity, and
venous anatomy, as well as preexisting valvular is-
sues. Special consideration also needs to be given
to this unique population due to somatic growth,
requirements for long-term pacing, and potential
alterations in the cardiovascular hemodynamics.
Advancement in endocardial transvenous leads
technology has offered pediatric/congenital heart
electrophysiologists improved equipment to
perform lead implant in younger patients and
those with complex CHD without significant in-
creases in procedure-related short- and long-term
Figure 3. Venous complications associated with use of
larger diameter pacing leads in the young is illustrated
in this venogram from a patient post-CHD repair viewed
in the anteroposterior projection. The 6-Fr diameter
lead was implanted when the patient was 9 years
of age and the viewed venogram was taken 4 years
later. There is severe narrowing and nearly complete
occlusion at the superior vena cava-innominate vein
junction with compensatory enlargement of both
azygous and hemiazygous veins acting to decompress
the obstruction. CHD = congenital heart defects.
complications. Additionally, selective-site pacing
and cardiac resynchronization therapy offers
better pacing outcomes on cardiac function.24
Due to the nature of the coaxial lead design,
the 4.1-Fr bipolar lumenless lead’s cross-sectional
area is reduced by 40% when compared to
standard, stylet-delivered, 5–7-Fr diameter leads.
This facilitates use in pediatric patients with
relatively smaller cardiac sizes, venous dimen-
sions, and AVV cross-sectional areas. The lead
diameters are visually different (Fig. 1). The
4.1-Fr M3830 has demonstrated favorable acute
and chronic performance with low complication
rates.13–19,27,28 A more recent study by Garnreiter
et al. also showed encouraging results for ease
of manual lead extraction.18 Webster et al.
have reported the association between PLs and
tricuspid insufficiency in children and patients
with congenital heart disease.6 AVVI following
ventricular lead placement can occur via multiple
mechanisms, includingmechanical causes such as
lead adherence to the valve tissue and scar forma-
tion as well as changes in ventricular activation
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timing causing poor valve leaflet coaptation.1,2,5
Our study further expands this finding by
demonstrating worsening of AVVI only after 2–
3 years postimplantation and not within the first
month. We speculate that late-onset insufficiency
is related to chronic lead-tissue interactions, not
acute mechanical leaflet tethering.
Our study is the first to directly compare
both the chronic impact on AVVs and venous
diameters between the 4.1 and standard 5–7-Fr
leads in the same cohort of young and congenital
heart patients. The overall incidence of AVVI
for all leads in our patient population was 20%,
similar to the pediatric CHD study published
previously.6 However, this study shows that
most adverse valve issues were associated with
larger diameter leads. The lumenless lead was
associated with less adverse impact on AVV
integrity. Due to simple timing logistics, long-term
echocardiographic data, up to 9 years postimplant,
were not available on all of the 4.1-Fr leads
when both lead diameter groups were compared.
Since the 4.1 leads first became available in 2005,
the mean follow-up in this group was 4.3 years
compared to the standard 5–7 Fr implanted prior
to 2005 which had the mean follow-up of 6 years.
However, worsening in AVVI degree occurred
within the first 2 years postimplant, during which
data on all leads were available. Therefore, we
considered this as adequate long-term follow-
up data. Our study did not suggest that change
in ventricular function impacted the degree of
AVVI since there were no changes in ventricular
contractility at the time of detection. Although
the majority of worsening AVVI occurred on one
nominal scale in our study, patients in the larger
diameter 5–7-Fr lead group demonstrated more
severe AVVI within a 5-year follow-up interval,
with significant hemodynamic impact requiring
some patients to undergo tricuspid valvuloplasty
or replacement. As indicated above, leads were
implanted to achieve optimal ventricular con-
tractility response.24 Therefore, implant locations
were variable along the ventricular septum.
However, due to concerns for elevated pacing
thresholds, especially among younger patients,
none of the leads were implanted to attempt “His
bundle/para-His” pacing, so lead insertion in very
close proximetry to the septal leaflet did not occur.
Partial venous obstruction is another pacing-
related complication associated with transvenous
PLs, especially in the young and those with
abnormal venous anatomy. Detection of venous
obstruction or occlusion can be challenging as
patients often do not develop any symptoms
initially due to development of collaterals and
potential azygous vein decompression. Although
significant venous abnormalities can be detected
echocardiographically, this is not as sensitive
as venography for milder degrees of venous
obstruction.23 In addition, some repaired CHDs
preclude accurate echocardiographic evaluations
of venous patency.29
Our study quantitatively reviewed the chronic
systemic venous effects among patients with both
the 4.1 and more standard 5–7-Fr diameter PLs
alone and in combination. The overall incidence
of angiographically significant systemic venous
obstruction was 17%, similar to the previously
published pediatric cohorts.23 However, the in-
cidence of narrowing was more prevalent in
the standard 5–7-Fr lead group compared to
the 4.1-Fr lumenless lead group. Also, this
study demonstrates the adverse impact of larger
diameter PLs on vascular growth in the young.
Limitations
A limitation for this study was the smaller
number of the Group 1 patients who completed
9-year follow-up echocardiogram/Doppler studies
when compared to Group 2 patients. This is
a chronological logistics issue that continued
clinical evaluations will rectify. All patients in
both groups had an echocardiogram performed at
baseline and at 1-month follow-up. However, all
patients had 3 years and the majority at least up to
4 years of serial echocardiogram/Doppler studies
for evaluation of AVV function. Based on clinical
findings, it would be anticipated that any chronic
AVV change should become evident during this
available follow-up period. Unfortunately, due to
limited number of patients in the Group 2 lead
diameter subsets, further breakdown comparisons
with the 4-Fr diameter lead was not feasible to
provide any valid statistical significance. So the
5-6-7-Fr diameter leads were grouped together.
Conclusions
Cardiac pacing initiated in the young inher-
ently is associated with potentially more adverse
issues than if pacing is initiated later in life. Recent
improvements and advances in PL technology
have benefitted pacing applications in the young.
The lumenless 4.1-Fr design has previously been
shown to be associated with stable chronic
pacing/sensing characteristics as well as ease
of extraction. This study contributes additional
information by demonstrating improved clinical
benefits on AVV and venous integrities. This is
a very important concept in growing children
who require long-term permanent pacing for
which any PL-induced adverse AVV issues or
delayed or arrest in systemic venous growth
as well as obstruction can be associated with
clinical morbidities and negatively impact patient
well-being.
PACE, Vol. 38 November 2015 1349
BHARMANEE, ET AL.
References
1. Sakai M, Ohkawa S, Ueda K, Kin H, Watanabe C, Matsushita S,
Kuramoto K, et al. Tricuspid regurgitation induced by transvenous
right ventricular pacing: Echocardiographic and pathological
observations. J Cardiol 1987; 17:311–320.
2. Paniagua D, Aldrich HR, Lieberman EH, Lamas GA, Agatston
AS. Increased prevalence of significant tricuspid regurgitation in
patients with transvenous pacemakers leads. Am J Cardiol 1998;
82:1130–1132.
3. Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM 3rd,
Hayes DL. Severe symptomatic tricuspid valve regurgitation due
to permanent pacemaker or implantable cardioverter defibrillator
leads. J Am Coll Cardiol 2005; 45:1672–1675.
4. Kim JB, Spevack DM, Tunick PA, Bullinga JR, Kronzon I, Chinitz
LA, Reynolds HR. The effect of transvenous pacemaker and
implantable cardioverter defibrillator lead placement on tricuspid
valve function: An observational study. J Am Soc Echocardiogr
2008; 21:284–287.
5. Al-Bawardy R, Krishnaswamy A, Bhargava M, Dunn J, Wazni
O, Tuzcu EM, Stewart W, et al. Tricuspid regurgitation in
patients with pacemakers and implantable cardiac defibrillators:
A comprehensive review. Clin Cardiol 2013; 36:249–254.
6. Webster G, Margossian R, Alexander ME, Cecchin F, Triedman JK,
Walsh EP, Berul CI. Impact of transvenous ventricular pacing leads
on tricuspid regurgitation in pediatric and congenital heart disease
patients. J Interv Card Electrophysiol 2008; 21:65–68.
7. Da Costa SS, Scalabrini NA, Costa R, Caldas JG, Martinelli FM.
Incidence and risk factors of upper extremity deep vein lesions
after permanent transvenous pacemaker implant: A 6-month follow-
up prospective study. Pacing Clin Electrophysiol 2002; 25:1301–
1306.
8. Bracke F, Meijer A, VanGelder B. Venous occlusion of the access
vein in patients referred for lead extraction: Influence of patient
and lead characteristics. Pacing Clin Electrophysiol 2003; 26:1649–
1652.
9. Melzer C, Lembcke A, Ziemer S, Eddicks S, Witte J, Baumann G,
Borges AC. Pacemaker-induced superior vena cava syndrome: Clin-
ical evaluation of long-term follow-up. Pacing Clin Electrophysiol
2006; 29:1346–1351.
10. Singh M, Talab SK. A case of pacing lead induced clinical superior
vena cava syndrome: A case report. Cases J 2009; 2:7477.
11. Senthilvel E, Papadakis A, Jain V, Bruner J. Pacemaker induced
superior vena cava syndrome: A case report. Cases J 2009; 2:6463.
12. Klop B, Scheffer MG, McFadden E, Bracke F, vanGelder B.
Treatment of pacemaker-induced superior vena cava syndrome by
balloon angioplasty and stenting. Neth Heart J 2011; 19:41–46.
13. Khan A, Zelin K, Karpawich PP. Performance of the lumenless
4.1-Fr diameter pacing lead implanted at alternative pacing sites
in congenital heart: A chronic 5-year comparison. Pacing Clin
Electrophysiol 2010; 33:1467–1474.
14. Gammage MD, Lieberman RA, Yee R, Manolis AS, Compton SJ,
Khazen C, Schaaf K, et al. Multi-center clinical experience with
a lumenless, catheter-delivered, bipolar, permanent pacemaker
lead: Implant safety and electrical performance. Pacing Clin
Electrophysiol 2006; 29:858–865.
15. Tuzcu V. Implantation of select secure leads in children. Pacing
Clin Electrophysiol 2007; 30:831–833.
16. KennyD,Walsh KP. Noncatheter-based delivery of a single chamber
lumenless pacing lead in small children. Pacing Clin Electrophysiol
2007; 30:834–838.
17. Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin
RP, Turner MS, et al. Initial experience of pacing with a lumenless
lead system in patients with congenital heart disease. Pacing Clin
Electrophysiol 2009; 32:1428–1433.
18. Garnreiter J, Whitaker P, Pilcher T, Etheridge S, Saarel E.
Lumenless pacing leads: Performance and extraction in pediatrics
and congenital heart disease. Pacing Clin Electrophysiol 2015;
38:42–47.
19. Gabbarini F, Agnoletti G. Selective-site pacing in paediatric
patients: Use of the SelectSecure System and risk of vein occlusion.
Europace 2010; 12:1286–1289.
20. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft
CD, Levine RA, Nihoyannopoulos, et al. Recommendations
for evaluation of the severity of native valvular regurgitation
with two-dimensional and Doppler echocardiography. J Am Soc
Echocardiogr 2003; 16:777–778.
21. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A,
Griffin BP, Lung B, et al. Echocardiographic assessment of valve
stenosis: EAE/ASE recommendations for clinical practice. J Am Soc
Echocardiogr 2009; 22:1–23.
22. Sanjeev S, Karpawich PP. Superior vena cava and innominate vein
dimension in growing children: An aid for interventional devices
and transvenous leads. Pediatr Cardiol 2006; 27:414–418.
23. Figa FH, McCrindle BW, Bigras JL, Hamilton RM, Gow RM. Risk
factors for venous obstruction in children with transvenous pacing
leads. Pacing Clin Electrophysiol 1997; 20:1902–1909.
24. Karpawich PP, Singh H, Zelin K. Optimizing paced ventricular
function in patients with and without repaired congenital
heart disease by contractility-guided lead implant. Pacing Clin
Electrophysiol 2014; 38: 54–62.
25. Deshmukh P, Casavant D, RomanyshynM, Anderson K. Permanent,
direct His-bundle pacing. A novel approach to cardiac pacing in
patients with normal His-Purkinje activation. Circulation 2000;
101:869–877.
26. Kapa S, Bruce C, Friedman P, Asirvatham S. Advances in cardiac
pacing: Beyond the transvenous right ventricular apical lead.
Cardiovasc Ther 2010; 28:369–379.
27. Cantu` F, DeFilippo P, Gabbarini F, Borghi A, Brambilla R, Ferrero P,
Comisso J, et al. Selective-site pacing in paediatric patients: A new
application of the Select Secure system. Europace 2009; 11:601–
606.
28. Daccarett M, Segerson NM, Bradley DJ, Etheridge SP, Freedman
RA, Saarel EV. Bipolar lumenless lead performance in children
and adults with congenital heart disease. Congenit Heart Dis 2010;
5:149–156.
29. Patel S, Shah D, Chintala K, Karpawich PP. Clinically unrecognized
atrial baffle complications following the Mustard operation in
young adults with D-transposition of the great arteries: Improved
detection is required. Congenit Heart Dis 2011; 6:466–474.
1350 November 2015 PACE, Vol. 38
